HIGH-GRADE B-CELL LYMPHOMA

This is a first-in-human study testing a new type of personalized cell therapy called CD79b-19 CAR T cells for adults with Non-Hodgkin Lymphoma that has come back or not responded to prior treatments. The main goal is to find a safe dose of these modified immune cells, which are …

This is a first-in-human study testing the safety and early effectiveness of a new, single-infusion CAR-T cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T …

This early-stage study is testing a new oral medication called SGR-1505 in adults with advanced B-cell cancers that have returned or stopped responding to previous treatments. The main goal is to find the highest safe dose and understand how the drug affects the body. Researchers…

This early-stage study is testing the safety of a new type of cancer treatment called P-CD19CD20-ALLO1 in adults with specific B-cell lymphomas that have come back or not responded to standard therapies. The treatment involves giving patients a single infusion of specially engine…

This is a first-in-human study testing a new personalized cell therapy called CLIC-2201 for adults and children with B-cell blood cancers that have returned or not responded to other treatments. The therapy involves collecting a patient's own immune cells, genetically modifying t…

This study is testing whether adding a maintenance drug called acalabrutinib after cellular therapies (like stem cell transplants or CAR-T cell therapy) can help prevent aggressive lymphoma from returning in patients at very high risk of relapse. Researchers want to see if this e…

This study is testing whether adding newer drugs (glofitamab, polatuzumab, and obinutuzumab) to standard lymphoma treatment works better for older adults with aggressive B-cell lymphoma. Researchers want to see if this combination can effectively control the cancer while causing …

This study is testing whether adding three new immunotherapy drugs (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy is safe and effective for people newly diagnosed with aggressive B-cell lymphomas. The trial will enroll about 35 adults to see if this combinati…

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This study is testing whether adding one of two new drugs (tazemetostat or zanubrutinib) to an existing two-drug therapy works better for controlling an aggressive type of blood cancer called large B-cell lymphoma. It is for adults whose cancer has returned or did not respond to …

This early-stage study is testing a new antibody drug called AZD0486 in people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to previous treatments. Researchers will give increasing doses to about 317 participants to find the safest amount and check for…

This study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…

This study is testing if a special blood test can help doctors personalize treatment for a common type of lymphoma called DLBCL. The goal is to see if patients who show no signs of cancer in their blood halfway through standard chemotherapy can safely stop the chemo drugs early a…

This study is testing a new method to find early signs that aggressive B-cell lymphoma might spread to the brain and spinal cord (central nervous system). Researchers will analyze spinal fluid from 50 high-risk patients using a sensitive DNA test to see if it can detect cancer ce…

This study aims to understand how specific genetic changes in a gene called MYC affect the course and treatment response of two aggressive types of B-cell lymphoma. Researchers will analyze tissue samples and medical records from 200 patients who have already been treated, lookin…